HC Wainwright Reiterates Buy Rating for Aquestive Therapeutics (NASDAQ:AQST)

HC Wainwright reissued their buy rating on shares of Aquestive Therapeutics (NASDAQ:AQST) in a research report released on Monday morning,Benzinga reports. HC Wainwright currently has a $10.00 price target on the stock. HC Wainwright also issued estimates for Aquestive Therapeutics’ Q1 2025 earnings at ($0.17) EPS, Q2 2025 earnings at ($0.15) EPS, Q3 2025 earnings at ($0.14) EPS, Q4 2025 earnings at ($0.15) EPS, FY2025 earnings at ($0.61) EPS and FY2026 earnings at ($0.56) EPS.

Several other research analysts have also recently commented on the stock. Cantor Fitzgerald began coverage on shares of Aquestive Therapeutics in a report on Tuesday, December 17th. They issued an “overweight” rating and a $17.00 target price for the company. Lake Street Capital decreased their target price on shares of Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating for the company in a report on Friday, March 7th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $10.57.

Aquestive Therapeutics Trading Up 11.4 %

NASDAQ:AQST opened at $2.94 on Monday. Aquestive Therapeutics has a twelve month low of $2.24 and a twelve month high of $6.23. The company has a 50-day moving average of $3.04 and a 200-day moving average of $4.07. The firm has a market cap of $290.68 million, a price-to-earnings ratio of -6.53 and a beta of 2.76.

Aquestive Therapeutics (NASDAQ:AQST) last posted its quarterly earnings data on Wednesday, March 5th. The company reported ($0.19) earnings per share for the quarter, missing the consensus estimate of ($0.14) by ($0.05). The firm had revenue of $11.87 million for the quarter, compared to the consensus estimate of $13.11 million. On average, research analysts forecast that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Hedge Funds Weigh In On Aquestive Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. New York State Common Retirement Fund raised its position in Aquestive Therapeutics by 713.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock valued at $43,000 after acquiring an additional 10,700 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in shares of Aquestive Therapeutics in the fourth quarter valued at approximately $44,000. Two Sigma Advisers LP bought a new position in shares of Aquestive Therapeutics in the fourth quarter valued at approximately $57,000. PKS Advisory Services LLC bought a new position in shares of Aquestive Therapeutics in the fourth quarter valued at approximately $63,000. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Aquestive Therapeutics in the fourth quarter valued at approximately $69,000. Institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.